Brief: Spago Nanomedical: Phase I/IIa Study Tumorad-01 Continues

Spago Nanomedical AB (publ)

27/08/2024 08:45

Aug 27 (Reuters) - Spago Nanomedical AB (publ)
 SPAGO.ST :
    * SPAGO NANOMEDICAL'S PHASE I/IIA STUDY TUMORAD-01 CONTINUES
FOLLOWING SUCCESSFUL TREATMENT COMPLETION OF FIRST PATIENT GROUP
    * STUDY PROCEEDS ACCORDING TO PLAN WITH RECRUITMENT OF
PATIENTS AT
TWO HOSPITALS ACTIVATED SO FAR.
    * NEXT DMC EVALUATION IS EXPECTED TO OCCUR AFTER 3
ADDITIONAL
PATIENTS COMPLETE A FIRST TREATMENT CYCLE

Source text for Eikon:  ID:nMFN7NB5sv 
Further company coverage:  SPAGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))